Urine Test May Reduce Unnecessary Prostate Cancer Biopsies

A new urine test, MyProstateScore 2.0 (MPS2), has shown high sensitivity in detecting aggressive prostate cancer without requiring a digital rectal exam. This advancement could help reduce unnecessary biopsies and MRIs for men with lower-risk disease.

A study of 266 men found that MPS2 outperformed PSA testing and the Prostate Cancer Prevention Trial Risk Calculator (PCPTrc) in identifying clinically significant prostate cancer (Grade Group 2 or higher). MPS2 had an area under the curve (AUC) of 77%, compared to 57% for PSA testing. The test could prevent 36% to 42% of unnecessary biopsies, and for men with prior negative biopsies, it could reduce repeat biopsies by up to 53%.

MPS2 is a molecular diagnostic test that analyzes 18 genes specific to prostate cancer, providing a more precise assessment of cancer risk. It has a high negative predictive value (95%-99%), meaning a negative result strongly suggests the absence of aggressive cancer.

Future research will explore its role in monitoring men with low-risk prostate cancer, potentially reducing the need for frequent MRIs and biopsies. This innovative test may improve patient comfort, lower healthcare costs, and refine prostate cancer management.

Byrne, J. (2025, March 10). Urine test may detect aggressive prostate cancer, eliminate need for some biopsies. Healio. https://www.healio.com/news/hematology-oncology/20250306/urine-test-may-detect-aggressive-prostate-cancer-eliminate-need-for-some-biopsies